Cintirorgon

®

MedChemExpress

Cat. No.:	HY-104037			
CAS No.:	2055536-64-4			
Molecular Formula:	C ₂₇ H ₂₃ F ₆ NO ₆ S			
Molecular Weight:	603.53			
Target:	ROR			
Pathway:	Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor			
Storage:	Powder	-20°C	3 years	
		4°C	2 years	
	In solvent	-80°C	2 years	
		-20°C	1 year	

SOLVENT & SOLUBILITY

In Vitro	DMSO : ≥ 113.3 mg/m Ethanol : 100 mg/mL * "≥" means soluble,	uL (187.73 mM) (165.69 mM; Need ultrasonic) but saturation unknown.						
	Solvent Mass Concentration	1 mg	5 mg	10 mg				
	Preparing Stock Solutions	1 mM	1.6569 mL	8.2846 mL	16.5692 mL			
		5 mM	0.3314 mL	1.6569 mL	3.3138 mL			
	10 mM	0.1657 mL	0.8285 mL	1.6569 mL				
	Please refer to the solubility information to select the appropriate solvent.							
In Vivo	1. Add each solvent Solubility: ≥ 2.5 m	one by one: 5% DMSO >> 40% PEG3 g/mL (4.14 mM); Clear solution	300 >> 5% Tween-80	>> 50% saline				

Description	Cintirorgon (LYC-55716) is a first-in-class, selective and orally bioavailable RORγ agonist. Cintirorgon (LYC-55716) modulates gene expression of RORγ expressing T lymphocyte immune cells, resulting in enhanced effector function, as well as decreased immunosuppression, resulting in decreased tumor growth, and improved survival ^{[1][2]} .				
IC ₅₀ & Target	RORy ^[1]				
In Vivo	Upon oral administration of RORy agonist Cintirorgon (LYC-55716), this agent selectively binds to the nuclear receptor transcription factor RORy, forming a receptor complex that translocates to the nucleus, and binds to ROR response elements (ROREs), enhancing the function, proliferation and survival of type 17 T cells, including Th17 (helper T cells) and Tc17 (cytotoxic T cells). RORy, the nuclear receptor transcription factor that is involved in Th17/Tc17 differentiation, plays a				

Product Data Sheet

он

0=\$=0

key role in immune activation. Cintirorgon (LYC-55716) is also orally bioavailable, while the new generation of immunooncology drugs-ncluding PD-1/PD-L1 inhibitors are delivered by injection^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- Pharmacol Res. 2021 Jul 30;105793.
- Diabetes. 2023 Aug 8;db220605.
- Antiviral Res. 2023 Dec 4:105769.
- Eur J Med Chem. 2021, 113585.
- Heliyon. 2023 Jun 28.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Lycera Announces Initiation of Phase 1/2a Study ARGON of Immuno-Oncology Candidate LYC-55716 in Patients with Advanced Solid Tumors. Jan 04, 2017.

Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA